reports
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Hig...
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter and year ended June 30, 2025. “We rema...
Harrow Announces Second-Quarter 2025 Financial Results
Harrow Announces Second-Quarter 2025 Financial Results Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA of $17.0 millionCash and cash equivalents of $53.0 million as of June 30, 2025 NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the second quarter ended June 30, 2025. The Company also posted its second quar...
Legacy Housing Corporation Reports Second Quarter 2025 Financial Resul...
Legacy Housing Corporation Reports Second Quarter 2025 Financial Results BEDFORD, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Legacy Housing Corporation (“Legacy” or the “Company,” NASDAQ: LEGH) today announced its financial results for the second quarter ended June 30, 2025. Financial Highlights Net revenue for the second quarter of 2025 was $50.2 million, an increase of 18.0% from the second quarter of 2024.Income from operations for the second quarter of 2025 was $16.8 million, an increase of 4.9% from the second quarter of 2024.Net income for the second quarter of 2025 was $14.7 millio...
Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conferen...
Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright’s 5th Annual Ophthalmology Conference on Wednesday, August 13, 2025, being held virtually. Harrow’s Chief Executive Officer, Mark L. Baum, and Chief Financial Officer, Andrew Boll, will participate in a fireside chat on Wednesday, August 13 at 8:30 a.m. Eastern time. In addition, Mark will participate in a panel discuss...
Harrow To Report Second Quarter 2025 Financial Results After Market C...
Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 12, 2025 NASHVILLE, Tenn., July 29, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2025, on Monday, August 11, 2025, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section of its website, . Har...
Legacy Housing Corporation Announces Timing of Second Quarter 2025 Ear...
Legacy Housing Corporation Announces Timing of Second Quarter 2025 Earnings Release and Conference Call BEDFORD, Texas, July 28, 2025 (GLOBE NEWSWIRE) -- Legacy Housing Corporation (“Legacy” or the “Company”, NASDAQ: LEGH) will release its financial results for the second quarter ended June 30, 2025, after markets close on Thursday, August 7, 2025. The Company will then host a conference call at 10:00 a.m. Central Time on Friday, August 8, 2025. To access the conference call, please pre-register using this . Registrants will receive confirmation with dial-in details. A replay of the web...
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the H.C. Wainwright “HCW@Home” Series. H.C Wainwright “HCW@Home with Nkarta, Inc.”July 30, 202511:00 a.m. ET – fireside chat Register for the webcast . A simultaneous webcast of the event will also be available on the Investors section of Nkarta’s website, , and a replay will be archived on the ...
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Comp...
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pur...
Nkarta Reports First Quarter 2025 Financial Results and Corporate High...
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash ...
Legacy Housing Corporation Reports First Quarter 2025 Financial Result...
Legacy Housing Corporation Reports First Quarter 2025 Financial Results BEDFORD, Texas, May 12, 2025 (GLOBE NEWSWIRE) -- Legacy Housing Corporation (“Legacy” or the “Company,” NASDAQ: LEGH) today announced its financial results for the first quarter ended March 31, 2025. Financial Highlights Net revenue for the first quarter of 2025 was $35.7 million, a decrease of 17.5% from the first quarter of 2024.Income from operations for the first quarter of 2025 was $11.6 million, a decrease of 30.8% from the first quarter of 2024.Net income for the first quarter of 2025 was $10.3 million, a dec...
Legacy Housing Corporation Announces Timing of First Quarter 2025 Earn...
Legacy Housing Corporation Announces Timing of First Quarter 2025 Earnings Release and Conference Call BEDFORD, Texas, April 29, 2025 (GLOBE NEWSWIRE) -- Legacy Housing Corporation (“Legacy” or the “Company”, NASDAQ: LEGH) will release its financial results for the first quarter ended March 31, 2025, after markets close on Monday, May 12, 2025. The Company will then host a conference call at 10:00 a.m. Central Time on Tuesday, May 13, 2025. To access the conference call, please pre-register using this . Registrants will receive confirmation with dial-in details. A replay of the webcast...
Nkarta to Participate in an April Investor Conference
Nkarta to Participate in an April Investor Conference SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 24th Annual Needham Virtual Healthcare ConferenceApril 8, 202511:00 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is...
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and...
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune indications expected in second half of 2025Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestonesCash b...
Legacy Housing Corporation Reports Full Year 2024 Financial Results
Legacy Housing Corporation Reports Full Year 2024 Financial Results BEDFORD, Texas, March 12, 2025 (GLOBE NEWSWIRE) -- Legacy Housing Corporation (the "Company” or “Legacy", NASDAQ: LEGH) today announced its financial results for the full year end December 31, 2024. Financial Highlights Net revenue for the year ended 2024 was $184.2 million, a decrease of 2.6% from the year ended 2023.Income from operations for the year ended 2024 was $63.6 million, a decrease of 1.5% from the year ended 2023.Net income for the year ended 2024 was $61.6 million, an increase of 13.2% from the year ended ...
Legacy Housing Corporation Announces Timing of Full Year 2024 Earnings...
Legacy Housing Corporation Announces Timing of Full Year 2024 Earnings Release and Conference Call BEDFORD, Texas, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Legacy Housing Corporation (“Legacy” or the “Company”, NASDAQ: LEGH) will release its financial results for the full year ended December 31, 2024, after markets close on Wednesday, March 12, 2025. The Company will then host a conference call at 10:00 a.m. Central Time on Thursday, March 13, 2025. To access the conference call, please pre-register using this . Registrants will receive confirmation with dial-in details. A replay of the we...
Nkarta to Participate in March Investor Conferences
Nkarta to Participate in March Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences: TD Cowen 45th Annual Health Care ConferenceMarch 3, 20253:10 p.m. ET – fireside chat Leerink Partners 2025 Global Healthcare ConferenceMarch 10, 20253:00 p.m. ET – fireside chat A simultaneous webcast of the events will be available on the Investors section of Nkarta’s website, , and a re...
- Jay McCanless
- Jonathan Moreland
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myas...
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2 Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored Trial (IST) expands the development of NKX019 to neuromuscular autoimmune disease myasthenia gravis Patient dosing initiated and enrollment open in Ntrust-1 and IST of NKX019 in systemic lupus erythematosus Clinical data from Ntrust-1 and Ntrust-2 planned for 2025 SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE N...
Nkarta to Participate in an Upcoming Investor Conference
Nkarta to Participate in an Upcoming Investor Conference SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 7th Annual Evercore HealthCONx ConferenceDecember 4, 20242:10 p.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a c...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.